GlassScriptPhysician profile
Darren Andrade
NPI 1245464379
$6,067.67
in general payments reported to CMS, 2019-2025
33 companies · $1,295 in 2025
The $1,295 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $63.60 · 2021: $47.68 · 2022: $1,021 · 2023: $1,902 · 2024: $1,312 · 2025: $1,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,443 · Education: $26.55 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,442.69 |
| Education | $26.55 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,979.03 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $619.81 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $464.60 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $308.76 | 2019-2024 | Entyvio |
| Pfizer INC. | $294.21 | 2023-2025 | |
| Celgene Corporation | $269.88 | 2022-2023 | Zeposia |
| Boston Scientific Corporation | $265.39 | 2023-2025 | General - Hemostasis, Exalt Model D, Cre Pro |
| Braintree Laboratories, INC. | $220.26 | 2020-2023 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $202.28 | 2019-2024 | Linzess |
| Ardelyx, INC. | $190.10 | 2022-2024 | Ibsrela |
| Lilly USA, LLC | $147.19 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $141.66 | 2022-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $119.21 | 2024-2025 | Zenpep |
| Qol Medical, LLC | $97.95 | 2023-2025 | Sucraid, Sucraid |
| Davol INC. | $89.71 | 2025 | Arista |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $88.26 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $75.32 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $65.15 | 2022-2023 | Dificid |
| Ferring Pharmaceuticals INC. | $59.22 | 2020-2023 | Rebyota |
| Madrigal Pharmaceuticals | $54.36 | 2025 | Rezdiffra |
| Daiichi Sankyo INC. | $36.69 | 2019-2022 | |
| Sandoz INC. | $35.27 | 2023-2024 | Hyrimoz |
| Fresenius Kabi USA, LLC | $34.61 | 2023 | Idacio |
| Phathom Pharmaceuticals, INC. | $31.24 | 2025 | Voquezna |
| Allergan, INC. | $27.58 | 2019 | |
| Shire North American Group INC | $23.61 | 2019 | |
| Dova Pharmaceuticals | $22.08 | 2019 | |
| Genzyme Corporation | $21.11 | 2024 | |
| Celltrion USA INC. | $18.33 | 2025 | Vegzelma |
| Albireo Pharma, INC. | $17.10 | 2023 | Bylvay |
| Organon LLC | $16.59 | 2023 | Hadlima, Renflexis |
| Intercept Pharmaceuticals, INC. | $16.18 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.93 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darren Andrade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.